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Alternative splicingMyotonic dystrophy type 1 (DM1) is a genetic disorder in which multiple genes are aberrantly spliced. Sarco/
endoplasmic reticulum Ca2+-ATPase 1 (SERCA1) is one of these genes, and it encodes a P-type ATPase. SERCA1
transports Ca2+ from the cytosol to the lumen, and is involved in muscular relaxation. It has two splice variants
(SERCA1a and SERCA1b) that differ in the last eight amino acids, and the contribution of these variants to DM1
pathology is unclear. Here, we show that SERCA1b protein is highly expressed in DM1 muscle tissue, mainly
localised at fast twitch ﬁbres. Additionally, when SERCA1a and SERCA1b were overexpressed in cells, we found
that the ATPase and Ca2+ uptake activity of SERCA1a was almost double that of SERCA1b. Although the afﬁnity
for both ATP and Ca2+ was similar between the two variants, SERCA1b was more sensitive to the inner micro-
somal environment. Thus, we hypothesise that aberrant expression of SERCA1b in DM1 patients is the cause of
abnormal intracellular Ca2+ homeostasis.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Myotonic dystrophy type 1 (DM1) is a multisystem disorder. The
symptoms of DM1 include muscle symptoms such as weakness and
myotonia. Cardiac and cognitive defects, cataracts, insulin resistance,
and hormone deﬁciency in multiple organs are also important symp-
toms in DM1. The genomic mutation that results in DM1 is an aberrant
elongation of CTG triplet repeats located in the 3′-UTR region of the
Dystrophia myotonica protein kinase (DMPK) gene [1]. When elongated
CTG repeats are transcribed into mRNA, they inhibit normal function
of RNA-binding splicing factors by interacting with those factors, and
hence result in RNA toxicity [2]. This subsequently leads to abnormal
splicing of multiple genes throughout the body.
ATP2A1 is one of the genes that is aberrantly spliced in DM1
muscle. ATP2A1 encodes Sarco/endoplasmic reticulum Ca2+-ATPase 1
(SERCA1). SERCA1 has two isoforms (SERCA1a, the adult form, and
SERCA1b, the neonatal form) produced by the alternative splicing of
exon 22, which is included in SERCA1a, but not in SERCA1b (Fig. 1A).
During development, the expression of SERCA1 migrates from the
SERCA1b form to the SERCA1a form. Thus, in adult skeletal muscle
tissue, only SERCA1a is expressed. However, SERCA1bmRNA has been
detected in adult skeletal muscle from DM1 patients [3].iura).SERCA1 protein is a representative member of P-type ATPase trans-
porter that is exclusively located in the sarcoplasmic reticulum (SR) of
fast-twitch skeletal muscle; it functions to transport Ca2+ from the
cytosol to the lumen of the SR. Because it is the only pump that uptakes
Ca2+ to SR in fast-twitch skeletal muscle, SERCA1 is crucial for main-
taining intracellular Ca2+ homeostasis. Mutations in the ATP2A1 gene
cause Brody disease, which is characterised by abnormalities in muscle
relaxation after exercise [4]. The SR of Brody patients has half, or less,
Ca2+-dependent ATPase activity compared with the control group.
Because exon 22 contains a stop codon, SERCA1a is shorter
(994 amino acids) than SERCA1b (1001 amino acids), with the last
eight amino acids differing between the two. The last eight amino
acids (DPEDERRK) of SERCA1b are rich in hydrophilic amino acids, sug-
gesting a speciﬁc role in the SR. In earlier studies, the two isoformswere
compared to determine whether they have functional differences. The
results were contrary to expectations; ATPase and Ca2+ uptake activi-
ties were similar between the two SERCA1 isoforms [5]. As large
amounts of SERCA1a protein can be easily puriﬁed from rabbit thigh
muscle, its properties have been well characterised [6–8]. SERCA1b
has received less attention, most likely because it has similar activity
to SERCA1a and has a limited expression period.
The discovery of SERCA1 aberrant splicing in DM1muscle has raised
questions about the possible importance of SERCA1b. Additionally, in
DM1, cytosolic Ca2+ concentrations were reported to be increased [9],
indicating a functional difference, and a series of intracellular Ca2+
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Fig. 1. Detection of SERCA1b in DM1. A. Schematic diagram showing two SERCA1 splicing patterns in DM1 patients. Dotted line, unveriﬁed; solid line, veriﬁed. B. Western blot analysis of
SERCA1b and SERCA1 expressed in DM1 patients' biopsies detected by speciﬁc SERCA1b antibody or SERCA1 antibody. β-actin was used as a loading control. C1-5 indicates non-DM
individuals; D1-5 indicates DM1 patients. 5 μg protein per lane was loaded. RT-PCR analysis on SERCA1 splicing patterns of each individual was shown at the lowest panel. Black arrows
indicate SERCA1a or SERCA1b. C. SERCA1b speciﬁc band intensity ofWestern blot analysis in B. p=0.167, (n=5, Student's t-test, mean±SD). D. SERCA1b speciﬁc band intensity of RT-PCR
in B. ***p b 0.0001, (n= 5, Student's t-test, mean ± SD).
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Hence, identiﬁcation of the speciﬁc function of SERCA1b is needed.
Here, we re-examine the functional differences between SERCA1a
and SERCA1b. We ﬁrst analyse SERCA1b protein levels in muscle tissue
from DM1 patients. Next, we attempt to dissect the functional differ-
ences between the two isoforms by overexpressing them in cultured
cells, and we conduct further biochemical analyses on the ATPase activ-
ity of SERCA1b. Finally, we propose a new, SRECA1 splice-dependent
pathway in DM1 pathology.
2. Methods
2.1. DM1 muscles
Biopsieswere obtained from the skeletalmuscle ofﬁve patientswith
DM1 and ﬁve non-DM individuals (see Table S1). The individuals' range
in age is from 15 to 55. All samples were stored at−80 °C.
2.2. Western blot analysis
Biopsied muscles were homogenised with 10 times volume of
buffer A (10 mM MOPS-KOH pH 7.0, 10% sucrose, 0.1 mM EDTA, 1%
NP-40, and 0.1% protease inhibitor). Microsomes expressing SERCA1a
or SERCA1b were used as a protein sample directly. Proteins were
separated by SDS-PAGE on 10% polyacrylamide gels and transferred
onto polyvinylidene ﬂuoride (PVDF) membranes. SERCA1 antibody
(1:2500, MA3-912, Thermo Scientiﬁc, USA), SERCA1b antibody
(mentioned below, 1:2500), and Actin antibody (1:2500, A2066,
Sigma-Aldrich, USA) were used to detect each protein. Membranes
were analysed using a LAS3000 imager (Fujiﬁlm, Japan). The intensities
of band signals were quantiﬁed using MultiGauge software (Fujiﬁlm,
Japan). The polyclonal antibody against SERCA1b was made to order
byMBL, Japan, and generated by immunising rabbits (speciﬁc pathogenfree) with a synthesised peptide, CLEDPEDERRK, conjugated containing
Keyhole limpet hemocyanin at its N-terminus.
2.3. SERCA1 splicing assay
Total RNA was extracted from frozen sections using TRIzol reagent
(Life Technologies, USA) according to the manufacturers' instructions.
0.5 μg of total RNA was reverse transcribed using a PrimeScript 1st
Strand cDNA Synthesis kit (TAKARA BIO, Japan) with a 1:1 mixture of
oligo dT and random hexamer as primers. Splicing assay of SERCA1
was performed as described previously [12]. PCR cycles were modiﬁed
to 24 ampliﬁcation cycles. Band intensities were digitized and quanti-
ﬁed using Multi-gauge (Fujiﬁlm, Japan).
2.4. Immunohistochemistry
Frozen sections (10 μm) of muscle biopsy specimens were ﬁxed in
4% paraformaldehyde in PBS for 15 min at room temperature. Slides
were incubated with blocking buffer containing 3% BSA and 5% goat
serum in PBS for 15 min at 37 °C. Primary antibodies were diluted in
blocking buffer to an appropriate concentration and incubated for 2 h
at 37 °C. Primary antibody concentrations used in immunohistochemis-
try are as follows: SERCA1b (the same antibody used at Western blot
analysis), 1:100; SERCA1 (the same antibody used atWestern blot anal-
ysis), 1:100; MHCf (NCL-MHCf, Leica Biosystems, UK), 1:50; MHCs
(NCL-MHCs, Leica Biosystems, UK) 1:80; Laminin (ab11576, abcam,
USA), 1:50. Slides were then washed with PBS. Secondary antibodies
are Alexa-488 or Alexa-568 conjugated secondary goat antibodies
against mouse, rabbit and rat. All from Invitrogen, USA were diluted in
3% BSA in PBS at 1:500 for 1 h at room temperature. Images were
acquired with a confocal laser scanning microscope (FluoView FV10i;
Olympus, Japan).
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Human SERCA1 cDNA (pFN21AE0051, Kazusa DNAResearch Institute,
Japan)was sequenced and identiﬁed as SERCA1b. The SERCA1b coding se-
quence was ampliﬁed by PCR (forward: 5′-gcggatcGCTAGCagggag
cacaATGGAGGCCGCTCATGCT-3′; reverse: 5′-GGATCCgtcgacTCACTT
CCTTCTTTCATCTTCTGGATCCT-3′, Fasmac, Japan). Human SERCA1a
cDNA was obtained by modifying the 5′-end of human SERCA1b using
the same forwardprimer as for SERCA1b ampliﬁcation anda reverse prim-
er (5′-GGATCCgtcgacTTATCCCTCTAGGTAGTTCCGAGCAACGAA-3′). Both
sequences were subcloned into pIRES2-AcGFP vectors (Clontech, USA).
2.6. Cell culture and transfection
HEK293 cells were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) containing 10% fetal bovine serum (FBS) and incubated in 5%
CO2 at 37 °C. Constructs were transfected using CalPhos Mammalian
Transfection Kit (Clontech, USA) according to the manufacturer's
procedure. Cells were cultured for 48 h after transfection.
2.7. Microsome preparation
Microsomal fractions were prepared as previously reported [5]. To
avoid Ca2+ contamination from the buffer, ﬁnal buffer concentrations
were modiﬁed to 20 mM MOPS-NaOH (pH 7.0), 0.25 M sucrose, and
1 mM MgCl2 without Ca2+. The ﬁnal suspension was stored in small
aliquots in liquid N2 or at−80 °C.
2.8. Activity measurements
To conﬁrm that the amounts of SERCA1a and SERCA1b used in activ-
ity measurements are the same, the ratio of SERCA1a and SERCA1b
expressed in microsomes were determined by making a standard
curve measured by Western blot analysis on a diluted series of each
microsome fraction. Both SERCA1 isoforms were detected by SERCA1
antibody. ATPase activitywas assayed as reported previously [5]. The re-
action mixture consisted of 40 mMMOPS-KOH (pH 7.0), 100 mM KCl,
5 mM MgCl2, 1 mM EGTA, 0.1 mM ouabain, 5 mM NaN3, 5 mM
oxalate-KOH, 4 mM ATP (Ca2+-free), 15 μM thapsigargin (+/−),
10 μM Ca2+, and 80–100 μg/ml of microsomal protein. The reaction
was initiated by adding ATP and oxalate-KOH at 37 °C. At 2, 4, 6, and
8 min, 15 μl of the sample was removed. Released Pi (inorganic
phosphate) was quantiﬁed using a Malachite Green Phosphate Assay
Kit (BioAssay Systems, USA). Ca2+ uptake activity was assayed accord-
ing to [5], using the same reaction mixture as in ATPase activity mea-
surements. At different time points (0, 2, 5 min), 50 μl of sample
was ﬁltered through a 0.45-μm millipore membrane (HAWP01300,
Merk-Millipore, USA) and washed with 40 mM MOPS-KOH (pH 7.0),
100 mM KCl, and 2 mM LaCl3. The amount of Ca2+ transported into
the microsomes was quantiﬁed using a Polarized Zeeman Atomic
Absorption Spectrophotometer (Z2710, Hitachi High-Technologies,
Japan). For the measurements of Ca2+ dependency, free Ca2+ concen-
trations were calculated by WinMAXC 32 v2.51 (C. Patthon, Stanford
University, USA).
2.9. Statistical analysis
All statistical analysis was performed using GraphPad Prism 6
(GraphPad Software, USA) with methods described in each legend.
3. Results
3.1. SERCA1b is aberrantly expressed in skeletal muscle of DM1 patients
Previous reports have shown that SERCA1b mRNA levels are not
always correlated with protein levels [13]. Thus, before examining therole of SERCA1b, we needed to conﬁrm its protein expression in DM1
patients. We ﬁrst conducted a Western blot analysis on biopsies of
skeletal muscle tissue from DM1 patients. Western blot analysis was
conducted using a SERCA1b speciﬁc antibody (produced according
to [13]). Its speciﬁcity to SERCA1b was veriﬁed by using SERCA1a
or SERCA1b overexpressing HEK293 cells (mentioned below; see
Fig. 3B). SERCA1b protein was detected in skeletal muscle tissues of
DM1 patients, but not in tissue from non-DM individuals (Figs. 1B, C;
for molecular marker, see S1A, B). Expression of SERCA1b was not de-
tected in Western blots of D5 muscle tissue, however, its expression
was conﬁrmed by an immunohistochemistry analysis (S1C). These
results indicate that the SERCA1b mRNA detected in DM1 patients
(Fig. 1B, D, [3]) is translated into protein. Because SERCA1a has only
one speciﬁc amino acid at the C-terminus, it was difﬁcult to produce a
SERCA1a-speciﬁc antibody. As an alternative, we used pan-SERCA1 an-
tibody that reactswith both SERCA1a and SERCA1b. Using this antibody,
SERCA1 was detected in all samples, as expected (Figs. 1B and S1D).
3.2. SERCA1b mainly localises at type II ﬁbres in DM1 muscle tissue
To investigate the ﬁbre type that SERCA1b expresses, we co-stained
slices of biopsieswith SERCA1b andmyosin heavy chain antibodies. As a
result, SERCA1b mainly co-localised with myosin fast type heavy chain
(Fig. 2). This result showed that SERCA1b has similar localisation with
SERCA1a. We also noticed that lower degree of SERCA1b co-localised
with myosin slow type heavy chain (see the asterisk at the middle
panel in Fig. 2).
3.3. SERCA1b has a half the ATPase and Ca2+ uptake activities of SERCA1a
Wehypothesised that the aberrant expression of SERCA1bprotein in
DM1 patients might result in abnormal intracellular Ca2+ homeostasis,
so we attempted to compare functional differences by overexpressing
the two isoforms in cultured cells. To avoid any inﬂuence on SERCA1
activity, we expressed SERCA1a and SERCA1b without tag sequences
(Fig. 3A). Constructs were transfected into HEK293 cells, which express
no endogenous SERCA1a or SERCA1b protein (Fig. 3B, lane c). The over-
expression of both variants was conﬁrmed by Western blot analysis
(Fig. 3B, lane 1a, b).
Microsomal fractions were puriﬁed as described previously [5]. Pre-
vious studies have shown that under certain conditions, ATPase and
Ca2+ uptake activities can be uncoupled [14]. Therefore, we measured
two activities separately. Measurements of SERCA1b ATPase and Ca2+
uptake activity were approximately half of what was measured for
SERCA1a (Fig. 3C, D),which implies that thedecrease in Ca2+uptake ac-
tivity in SERCA1b is ATPase activity dependent. To conﬁrm that the
measured activities were not due to endogenous SERCA expression,
SERCA2 protein was analysed by Western blot, but no signal was
detected (Fig. S3). Thus, we concluded that the activities measured in
Fig. 3 were due to the overexpression of SERCA1.
3.4. SERCA1b has similar ATP-, Ca2+-, and pH-related ATPase activity
to SERCA1a, but has lower activity when the inner microsomal Ca2+
concentration is high
To further investigate the biochemical properties of SERCA1b,we fo-
cused on the ATP- and Ca2+-dependent ATPase activities (Fig. 4A,B).
The Km of SERCA1b for ATP is 0.32 ± 0.04 μM, and the K0.5 for Ca2+ is
0.22 ± 0.04 μM; these values are almost the same as those for SERCA1a
measured under the same condition (0.35 ± 0.05 μM for ATP and
0.22±0.04 μMfor Ca2+ (see Table 1)). For SERCA1a, these data are con-
sistent with previous reports [6,15]. However, themaximum velocity of
SERCA1b is approximately half that of SERCA1a (52 ± 2.0% for ATP,
57 ± 3.4% for Ca2+). As a result of this, the ATPase activity of SERCA1b
displayed ATP and Ca2+concentration dependence similar to that of




Fig. 2. SERCA1bmainly localise at type II ﬁbres in DM1muscle tissue. Immunohistochemistry staining of SERCA1b in DM1muscle tissue (D1, quadriceps femoris) with control (C4, biceps
brachii). Samples used at each panel were indicated at the left of the column. Primary antibodies used in each panel were indicated at the top of the columnwith appropriate colour that
corresponding to secondary antibodies. MHCf, myosin fast type heavy chain; MHCs, myosin slow type heavy chain; asterisk, SERCA1b expressed type I ﬁbres. Laminin were stained to
indicate outline of ﬁbres. Scale bar, 100 μm.
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SERCA1b. By changing the pH of the reaction buffer from pH 6.0 to
pH 7.9, we determined that the optimal pH was pH 7.0 (Fig. 4C). This
result is consistent with SERCA1a, which was measured under the
same conditions (Fig. 4C, [6,16]).
We were curious as to why SERCA1b has 50% lower activity com-
pared with SERCA1a, yet has approximately the same afﬁnity for ATP
and Ca2+ and the same optimum pH. To investigate the activity of
SERCA1b without inﬂuence from the inner microsomal environment,
we used A23187, a Ca2+ ionophore, to measure the ATPase activity.A
B C
Fig. 3. Comparison of ATPase and Ca2+ uptake activity of SERCA1a and SERCA1b. A. Schemati
SERCA1a and SERCA1b expressed in HEK293 cells detected by SERCA1b, while SERCA1 and b-ac
with SERCA1a/pIRES2-AcGFP vector; 1b, cells transfected with SERCA1b/pIRES2-AcGFP vector.
(C), *p b 0.05 (D) (n= 3, Student's t-test, mean ± SE).To our surprise, the ATPase activities of SERCA1b and SERCA1a were
similar with the addition of A23187 (Fig. 4D). This result indicates that
the lower activity of SERCA1b is caused by a high Ca2+ concentration
in the microsome.
4. Discussion
In this study, we identiﬁed functional differences between SERCA1
splicing variants, which were previously considered to have no
functional difference other than the well-conserved eight-amino-acidD
c diagram showing SERCA1a or SERCA1b vector construction. B. Western blot analysis of
tin antibodies. c, control cells (transfectedwith pIRES2-AcGFP vector); 1a, cells transfected
ATPase activity (C) and Ca2+ uptake activity (D) of SERCA1a and SERCA1b. ****p b 0.0001
A B
C D
Fig. 4. Biochemical analysis of ATPase activity of SERCA1b. ATP(A), Ca2+ (B) concentration dependence of SERCA1b ATPase activity. SERCA1a (●), SERCA1b (■). Approximate formula:
Y = Vmax*X/(Km + X), R2 = 0.94, n= 16 (A). Y = Vmax*Xh/(K0.5h + Xh), h = 1.3 ± 0.2, R2 = 0.96 (SERCA1a), 0.95 (SERCA1b), n= 13 (B). Vmax = mean ± SE. C. pH- (6.0, 6.6, 7.0, 7.4,
7.9) dependent SERCA1b ATPase activity (n= 3). At pH 6.0, MES-KOH buffer was used instead of MOPS-KOH. D. ATPase activity of SERCA1a and SERCA1b in the presence of A23187.
p= 0.45 (n= 3, Student's t-test, mean ± SE).
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SERCA1b protein was abnormally expressed in DM1 patients using
patient biopsies (Fig. 1B–D). We also showed that SERCA1b localises
mainly at fast twitch skeletal muscle tissue in vivo (Fig. 2). We noticed
that some slow-twitch ﬁbres express SERCA1b. This result suggests
that the regulation system of SERCA1 expression is affected in DM1.
Next, by overexpressing SERCA1 variants at HEK293 cells, we success-
fully measured the activity of both SERCA1b and SERCA1a, and deter-
mined that SERCA1b has approximately half the ATPase and Ca2+
uptake activity of SERCA1a (Fig. 3C,D). These results are inconsistent
with previous research [5]. However, we tested SERCA activity using
its speciﬁc inhibitor, namely thapsigargin, which was not available at
the time of the prior study [5] in 1988. Furthermore, the sensitivity to
thapsigargin was reported to be the same for SERCA1a and SERCA1b
[17]. Thus, the effect of thapsigarginmay explain thedifference between
the two reports.
We then tried to determine the speciﬁcs of SERCA1b ATPase activity,
and found that its ATP-, Ca2+-, and pH-dependent ATPase activity was
similar to that of SERCA1a, but with half the Vmax (Fig. 4A–C, Table 1).
However, these results could not explain differences between the two
variants. Therefore, we used A23187 to test whether the inner micro-
somal environmentwould change the activity ratio of the two isoforms.
Because A23187 makes holes in membranes, allowing Ca2+ to migrate
freely, the change in activity ratio observed in Fig. 4D could be explained
by the different reaction of two isoforms to inner microsomal Ca2+Table 1
Apparent afﬁnities and maximum velocities calculated according to Fig. 4A, B.
SERCA1a SERCA1b
ATP km(mM) 0.35 ± 0.05 0.32 ± 0.04
Vmax (%) 100 ± 4.1 52 ± 2.0
Ca2+ K0.5 (μM) 0.22 ± 0.04 0.22 ± 0.04
Vmax (%) 100 ± 6.1 57 ± 3.4concentrations. In other words, when the inner microsomal Ca2+
concentration is high (experiments with oxalic acid), SERCA1b has
only half the activity of SERCA1a, butwhen innermicrosomal Ca2+ con-
centration is low (experiments with A23187), the two isoforms have
similar activities. One possible explanation for this is that the reverse
reaction of ATP hydrolysis, ATP synthesis, may be facilitated in the pres-
ence of C-terminal of SERCA1b. These results strongly indicate that,
compared with SERCA1a, SERCA1b cannot fully uptake Ca2+ to the
microsome.
The ratio of protein expression of the two isoforms in DM1 is unclear
at present because SERCA1a has only one speciﬁc amino acid, so it is
hard to produce a speciﬁc antibody. However, the expression level of
SERCA1b is completely absent in control individuals (Fig. 1B). In
Fig. 4D, we can see that SERCA1b is more sensitive to inner microsomal
Ca2+. As SERCA1b cannot uptake asmuch Ca2+ as SERCA1a can, the cy-
tosolic high Ca2+ concentration reported in [9] may be due to aberrant
expression of SERCA1b. Thismay introducemany abnormalities inDM1.
One possible result of high Ca2+ concentration in the cytosol in DM1
is the hyper phosphorylation of CUGBP Elav-like family member 1
(CELF1 or CUGBP1), a splicing factor. In DM1 patients, it is known
that CTG repeats cause the hyperphosphorylation of CELF1 [18].
Hyperphosphorylation of CELF1 increases its steady-state level,
resulting in over-activation of CELF1 [19]. Although this phosphoryla-
tion alters multiple splicing events [20–22], the phosphorylation path-
way remains unclear. Our study in this paper may explain one of the
phosphorylation pathways of CELF1 (Fig. 5). The aberrant splicing of
SERCA1 is due to themuscle blind-like protein 1 (MBNL1) sequestration
induced by CTG repeats [23]. This splicing alteration results in aberrant
expression of SERCA1b at a protein level, and the low activity of
SERCA1b may induce high Ca2+ concentration in cytosol. Due to this,
protein kinase C (PKC), whose activation is introduced by Ca2+ binding,
will be activated. As it is known that PKC can hyperphosphorylate CELF1
[19], we hypothesise that the alternative splicing of SERCA1 can regulate
the hyperphosphorylation of CELF1 in an indirect manner, via Ca2+ and
Fig. 5. The hypothesis that a SERCA1 splicing-dependent pathway that leads to CELF1
activation in DM1. Dotted line, veriﬁed insufﬁciently; solid line, reported previously.
2047Y. Zhao et al. / Biochimica et Biophysica Acta 1852 (2015) 2042–2047PKC (Fig. 5). Thus, it is possible that SERCA1b expression contributes to
the Ca2+ abnormalities in DM1 patients, resulting in myotonia and
other symptoms.
5. Conclusions
To summarise, this is the ﬁrst report to identify SERCA1b protein ex-
pression and its localisation in DM1 patients and to show that the two
SRECA1 isoforms have functional differences. We have identiﬁed that
the underlying reason for the variants' differences may not be the
afﬁnities to ATP, Ca2+, or pH, but rather the inner microsomal environ-
ment, speciﬁcally, the inner microsomal Ca2+ concentration. These
ﬁndings suggest the existence of a SERCA1 splicing-dependent pathway
that leads to abnormal Ca2+ homeostasis. In conclusion, we have iden-
tiﬁed not only the functional differences in SERCA1 variants but also one
possible explanation for Ca2+ abnormalities in DM1 patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.07.006.
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